Physician profile
Paul Dcruz
NPI 1558361493
$7,133.10
in general payments reported to CMS, 2019-2025
21 companies · $420 in 2025
The $420 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $687 · 2020: $548 · 2021: $550 · 2022: $1,727 · 2023: $1,808 · 2024: $1,393 · 2025: $420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,621.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,620.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $1,229.80 | 2019-2024 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $688.31 | 2019-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $597.40 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $558.93 | 2021-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $551.94 | 2022-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $537.65 | 2020-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Corium, LLC | $496.04 | 2022-2025 | Azstarys |
| Axsome Therapeutics, INC. | $454.23 | 2024-2025 | Auvelity |
| Alkermes, INC. | $419.88 | 2021-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $363.76 | 2020-2024 | Austedo Xr, Uzedy, Austedo |
| Lundbeck LLC | $329.86 | 2020-2024 | Rexulti |
| Sunovion Pharmaceuticals INC. | $220.66 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $196.56 | 2022-2023 | Trintellix |
| Tris Pharma INC | $115.43 | 2022-2024 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $102.57 | 2019-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $99.64 | 2019 | |
| Allergan, INC. | $50.23 | 2020 | |
| Almatica Pharma LLC | $43.27 | 2021-2023 | Sertraline Hcl, Loreev Xr |
| Neos Therapeutics, LP | $33.53 | 2024-2025 | Exxua, Adzenys Xr-Odt |
| Vanda Pharmaceuticals INC. | $23.32 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $20.09 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Dcruz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.